Gilead to Acquire PepStar Therapeutics’ Oral IL-23R Inhibitor HCXT-2001, Strengthening Its IBD Inflammation Pipeline for $1.275 billion in Cash
On Oct. 22, 2026, Gilead Sciences announced that it has entered into a definitive agreement to acquire an…